Sanofi Completes Acquisition of Vigil Neuroscience, Strengthening Neurology Pipeline

Sanofi has completed its acquisition of Vigil Neuroscience, Inc. for $470 million, strengthening its early-stage pipeline in neurology with VG-3927, a novel oral TREM2 agonist for Alzheimer's disease. The acquisition also includes Vigil's preclinical pipeline for various neurodegenerative diseases. Sanofi's financial guidance for 2025 is not impacted.

Title: Sanofi Completes Acquisition of Vigil Neuroscience, Inc.

Sanofi has completed its acquisition of Vigil Neuroscience, Inc. for approximately $470 million in cash, with shares acquired at $8 per share. This strategic move aims to bolster Sanofi's early-stage pipeline in neurology, particularly with VG-3927, a novel oral TREM2 agonist being evaluated in a phase 2 clinical study for Alzheimer's disease. The acquisition also includes Vigil's preclinical pipeline for various neurodegenerative diseases [1].

The acquisition agreement includes a non-transferrable contingent value right (CVR) for Vigil's shareholders, entitling them to a deferred cash payment of $2 per share upon the first commercial sale of VG-3927. Notably, the acquisition of Vigil is not expected to impact Sanofi's financial guidance for 2025 [1].

Sanofi's investment in Vigil Neuroscience began in June 2024 with a $40 million strategic investment that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927 [1]. The acquisition of Vigil Neuroscience aligns with Sanofi's commitment to improving people’s lives through innovative medicines and vaccines, leveraging its deep understanding of the immune system [1].

Sanofi's forward-looking statements caution investors about various risks and uncertainties, including research and development outcomes, regulatory decisions, and market conditions. Despite these risks, the acquisition of Vigil Neuroscience positions Sanofi to potentially expand its market presence and contribute to advancements in the treatment of neurodegenerative diseases [1].

References
[1] https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-06-05-00-00-3128014